Bengaluru-based Fermbox Bio, a synthetic biology company that uses microbial precision fermentation for the sustainable and commercially viable production of bio-alternatives, has announced its collaboration agreement with Dyadic International Inc. This marks Dyadic’s first collaboration with an Indian company for non-pharmaceutical applications on the Dapibus platform and will bring together Fermbox’s extensive product development and scale-up process engineering capabilities and Dyadic’s proprietary filamentous fungal-based microbial protein production platform to design, develop, and commercialise innovative animal-free alternative proteins and biomaterials.
Having operations both in the US and in India, Fermbox is uniquely positioned to collaborate globally and use its advantage of access to Indian scientific talent and manufacturing capabilities locally. The partnership will allow Fermbox to leverage India’s expertise in gene expression and enzymatic pathway engineering to build highly productive microbial strains to develop a number of bioproducts. This capability, coupled with India’s strengths in low-cost manufacturing at industrial scale can propel the alternative protein sector, making India a viable supplier to the global industry.
This collaboration is a milestone in the synthetic biology industry that has the potential to influence and inspire others to follow similar models to increase success rates for product development and viable commercialisation.
As the global population rises and the need for nutritious and affordable food sources grow, India has the potential to be a leader in the development of sustainable alternatives that have the potential to feed a growing population while showcasing a model of growth for other emerging markets.
Image credit- shutterstock